The hypoxia imaging agent Cu ii(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease

Journal of Experimental Medicine

Volumn 209, Issue 4, 2012, Pages 837-854

  Hung, Lin W ^a,b   Villemagne, Victor L ^a,c   Cheng, Lesley ^a,b   Sherratt, Nicki A ^a,b   Ayton, Scott ^a   White, Anthony R ^a   Crouch, Peter J ^a   Lim, SinChun ^a,b   Leong, Su Ling ^a,b   Wilkins, Simon ^a   George, Jessica ^a   Roberts, Blaine R ^a   Pham, Chi L L ^a,b   Liu, Xiang ^a,b   Chiu, Francis C K ^d   Shackleford, David M ^d   Powell, Andrew K ^d   Masters, Colin L ^a   Bush, Ashley I ^a   O'Keefe, Graeme ^d   Culvenor, Janetta G ^a   Cappai, Roberto ^a,b   Cherny, Robert A ^a   Donnelly, Paul S ^a   Hill, Andrew F ^a,b   Finkelstein, David I ^a   Barnham, Kevin J ^a,b   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; COPPER DERIVATIVE; COPPER DIACETYLBIS[N(4) METHYLTHIOSEMICARBAZONATE)]; DOPAMINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NEUROPROTECTIVE AGENT; OLIGOMER; PEROXYNITRITE; SYNAPTOPHYSIN; THIOSEMICARBAZONE DERIVATIVE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2; 3 MORPHOLINO SYDNONIMINE; 3-MORPHOLINO-SYDNONIMINE; COPPER (II) DIACETYL DI(N(4) METHYLTHIOSEMICARBAZONE); COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); DRUG DERIVATIVE; MOLSIDOMINE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEWY BODY; MALE; MEMORY; MONOAMINE NERVE CELL; MOTOR PERFORMANCE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NITRATION; NONHUMAN; PALLIATIVE THERAPY; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; ANIMAL; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; MOTOR ACTIVITY; POSITRON EMISSION TOMOGRAPHY; PSYCHOLOGICAL ASPECT; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ALPHA-SYNUCLEIN; ANIMALS; CELL LINE, TUMOR; COGNITION; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED C57BL; MOLSIDOMINE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; ORGANOMETALLIC COMPOUNDS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; THIOSEMICARBAZONES;

EID: 84861728900     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20112285     Document Type: Article

References (102)

1. Alonso, A., L.A. Rodríguez, G. Logroscino, and M.A. Hernán. 2007. Gout and risk of Parkinson disease: a prospective study. Neurology. 69:1696-1700. http://dx.doi.org/10.1212/01.wnl.0000279518.10072.df
2. Andreadou, E., C. Nikolaou, F. Gournaras, M. Rentzos, F. Boufidou, A. Tsoutsou, C. Zournas, V. Zissimopoulos, and D. Vassilopoulos. 2009. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin. Neurol. Neurosurg. 111:724-728. http://dx.doi.org/10.1016/j.clineuro.2009.06.012
3. Baba, M., S. Nakajo, P.H. Tu, T. Tomita, K. Nakaya, V.M. Lee, J.Q. Trojanowski, and T. Iwatsubo. 1998. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152:879-884.
4. Beckman, J.S. 2009. Understanding peroxynitrite biochemistry and its potential for treating human diseases. Arch. Biochem. Biophys. 484:114-116. http://dx.doi.org/10.1016/j.abb.2009.03.013
5. Beckman, J.S., T.W. Beckman, J. Chen, P.A. Marshall, and B.A. Freeman. 1990. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA. 87:1620-1624. http://dx.doi.org/10.1073/pnas.87.4.1620
6. Beckman, J.S., M. Carson, C.D. Smith, and W.H. Koppenol. 1993. ALS, SOD and peroxynitrite. Nature. 364:584. http://dx.doi.org/10.1038/364584a0
7. Beckman, J.S., J. Chen, H. Ischiropoulos, and J.P. Crow. 1994. Oxidative chemistry of peroxynitrite. In Oxygen Radicals in Biological Systems, Pt C. Academic Press.
8. Blum, D., S. Torch, N. Lambeng, M.F. Nissou, A.L. Benabid, R. Sadoul, and J.M. Verna. 2001. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65:135-172. http://dx.doi.org/10.1016/S0301-0082(01)00003-X
9. Cappai, R., S.L. Leck, D.J. Tew, N.A. Williamson, D.P. Smith, D. Galatis, R.A. Sharples, C.C. Curtain, F.E. Ali, R.A. Cherny, et al. 2005. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J. 19:1377-1379.
10. Caudle, W.M., R.E. Colebrooke, P.C. Emson, and G.W. Miller. 2008. Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci. 31:303-308. http://dx.doi.org/10.1016/j.tins.2008.02.010
11. Cipriani, S., X.Q. Chen, and M.A. Schwarzschild. 2010. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomarkers Med. 4:701-712. http://dx.doi.org/10.2217/bmm.10.94
12. Contestabile, A. 2008. Regulation of transcription factors by nitric oxide in neurons and in neural-derived tumor cells. Prog. Neurobiol. 84:317-328. http://dx.doi.org/10.1016/j.pneurobio.2008.01.002
13. Culvenor, J.G., C.A. McLean, S. Cutt, B.C. Campbell, F. Maher, P. Jäkälä, T. Hartmann, K. Beyreuther, C.L. Masters, and Q.X. Li. 1999. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and α-synuclein are not associated with Abeta amyloid. Am. J. Pathol. 155:1173-1181. http://dx.doi.org/10.1016/S0002-9440(10)65220-0
14. Dauer, W., and S. Przedborski. 2003. Parkinson's disease: mechanisms and models. Neuron. 39:889-909. http://dx.doi.org/10.1016/S0896-6273(03)00568-3
15. de Lau, L.M., P.J. Koudstaal, A. Hofman, and M.M. Breteler. 2005. Serum uric acid levels and the risk of Parkinson disease. Ann. Neurol. 58:797-800. http://dx.doi.org/10.1002/ana.20663
16. De Vera, M., M.M. Rahman, J. Rankin, J. Kopec, X. Gao, and H. Choi. 2008. Gout and the risk of Parkinson's disease: a cohort study. Arthritis Rheum. 59:1549-1554. http://dx.doi.org/10.1002/art.24193
17. Dehmer, T., J. Lindenau, S. Haid, J. Dichgans, and J.B. Schulz. 2000. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 74:2213-2216. http://dx.doi.org/10.1046/j.1471-4159.2000.0742213.x
18. Dong, Z., B. Ferger, J. Feldon, and H. Büeler. 2002. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. J. Neurobiol. 53:1-10. http://dx.doi.org/10.1002/neu.10094
19. Donnelly, P.S., J.R. Liddell, S. Lim, B.M. Paterson, M.A. Cater, M.S. Savva, A.I. Mot, J.L. James, I.A. Trounce, A.R. White, and P.J. Crouch. 2012. An impaired mitochondrial electron transport chain increases retention of the hypoxia imaging agent diacetylbis(4-methylthiosemicarbazonato)copper II. Proc. Natl. Acad. Sci. USA. 109:47-52. http://dx.doi.org/10.1073/pnas.1116227108
20. Duda, J.E., B.I. Giasson, Q. Chen, T.L. Gur, H.I. Hurtig, M.B. Stern, S.M. Gollomp, H. Ischiropoulos, V.M. Lee, and J.Q. Trojanowski. 2000. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am. J. Pathol. 157:1439-1445. http://dx.doi.org/10.1016/S0002-9440(10)64781-5
21. Ebadi, M., and S.K. Sharma. 2003. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antioxid. Redox Signal. 5:319-335. http://dx.doi.org/10.1089/152308603322110896
22. Ennaceur, A., and J. Delacour. 1988. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav. Brain Res. 31:47-59. http://dx.doi.org/10.1016/0166-4328(88)90157-X
23. Feelisch, M., J. Ostrowski, and E. Noack. 1989. On the mechanism of NO release from sydnonimines. J. Cardiovasc. Pharmacol. 14:S13-S22.
24. Ferrante, R.J., P. Hantraye, E. Brouillet, and M.F. Beal. 1999. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Res. 823:177-182. http://dx.doi.org/10.1016/S0006-8993(99)01166-X
25. Finkelstein, D.I., D. Stanic, C.L. Parish, D. Tomas, K. Dickson, and M.K. Horne. 2000. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience. 97:99-112. http://dx.doi.org/10.1016/S0306-4522(00)00009-9
26. Finkelstein, D.I., D. Stanic, C.L. Parish, J. Drago, and M.K. Horne. 2004. Quantified assessment of terminal density and innervation. Curr. Protoc. Neurosci. Chapter 1, Unit 113.
27. Fodero-Tavoletti, M.T., V.L. Villemagne, B.M. Paterson, A.R. White, Q.X. Li, J. Camakaris, G.J. O'Keefe, R. Cappai, K.J. Barnham, and P.S. Donnelly. 2010. Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease. J. Alzheimers Dis. 20:49-55.
28. Freichel, C., M. Neumann, T. Ballard, V. Müller, M. Woolley, L. Ozmen, E. Borroni, H.A. Kretzschmar, C. Haass, W. Spooren, and P.J. Kahle. 2007. Age-dependent cognitive decline and amygdala pathology in alphasynuclein transgenic mice. Neurobiol. Aging. 28:1421-1435. http://dx.doi .org/10.1016/j.neurobiolaging.2006.06.013
29. Giasson, B.I., J.E. Duda, I.V. Murray, Q. Chen, J.M. Souza, H.I. Hurtig, H. Ischiropoulos, J.Q. Trojanowski, and V.M. Lee. 2000. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science. 290:985-989. http://dx.doi.org/10.1126/science.290.5493.985
30. Giasson, B.I., J.E. Duda, S.M. Quinn, B. Zhang, J.Q. Trojanowski, and V.M. Lee. 2002. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron. 34:521-533. http://dx.doi.org/10.1016/S0896-6273(02)00682-7
31. Good, P.F., A. Hsu, P. Werner, D.P. Perl, and C.W. Olanow. 1998. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57:338-342. http://dx.doi.org/10.1097/00005072-199804000-00006
32. Gundersen, H.J., P. Bagger, T.F. Bendtsen, S.M. Evans, L. Korbo, N. Marcussen, A. Møller, K. Nielsen, J.R. Nyengaard, B. Pakkenberg, et al. 1988. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS. 96:857-881. http://dx.doi.org/10.1111/j.1699-0463.1988.tb00954.x
33. Gupta, S.P., S. Patel, S. Yadav, A.K. Singh, S. Singh, and M.P. Singh. 2010. Involvement of nitric oxide in maneb- and paraquat-induced Parkinson's disease phenotype in mouse: is there any link with lipid peroxidation? Neurochem. Res. 35:1206-1213. http://dx.doi.org/10.1007/s11064-010-0176-5
34. Hantraye, P., E. Brouillet, R. Ferrante, S. Palfi, R. Dolan, R.T. Matthews, and M.F. Beal. 1996a. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med. 2:1017-1021. http://dx.doi.org/10.1038/nm0996-1017
35. Hantraye, P., E. Brouillet, R. Ferrante, S. Palfi, R. Dolan, R.T. Matthews, and M.F. Beal. 1996b. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med. 2:1017-1021. http://dx.doi.org/10.1038/nm0996-1017
36. Hassler, R. 1938. Pathologie der Paralysis agitans und des postenzephailitischen Parkinsonismus. J. Psychol. Neurol. 48:387-476.
37. 18F-AV-133: A Selective VMAT2-binding Radiopharmaceutical for PET Imaging of Dopaminergic Neurons. PET Clin. 5:75-82. http://dx.doi.org/10.1016/j.cpet.2010.02.001
38. Henze, C., C. Earl, J. Sautter, N. Schmidt, C. Themann, A. Hartmann, and W.H. Oertel. 2005. Reactive oxidative and nitrogen species in the nigrostriatal system following striatal 6-hydroxydopamine lesion in rats. Brain Res. 1052:97-104. http://dx.doi.org/10.1016/j.brainres.2005.06.020
39. Hooper, D.C., S. Spitsin, R.B. Kean, J.M. Champion, G.M. Dickson, I. Chaudhry, and H. Koprowski. 1998. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA. 95:675-680. http://dx.doi.org/10.1073/pnas.95.2.675
40. Ikawa, M., H. Okazawa, T. Kudo, M. Kuriyama, Y. Fujibayashi, and M. Yoneda. 2011. Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PET. Nucl. Med. Biol. 38:945-951. http://dx.doi.org/10.1016/j.nucmedbio.2011.02.016
41. Jackson-Lewis, V., and S. Przedborski. 2007. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protocol. 2:141-151.
42. Kanner, B.I., and S. Schuldiner. 1987. Mechanism of transport and storage of neurotransmitters. CRC Crit. Rev. Biochem. 22:1-38. http://dx.doi .org/10.3109/10409238709082546
43. Kastner, A., E.C. Hirsch, Y. Agid, and F. Javoy-Agid. 1993. Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease. Brain Res. 606:341-345. http://dx.doi .org/10.1016/0006-8993(93)91005-D
44. Kazantsev, A.G., and A.M. Kolchinsky. 2008. Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease. Arch. Neurol. 65:1577-1581. http://dx.doi.org/10.1001/archneur.65.12.1577
45. Langston, J.W., P. Ballard, J.W. Tetrud, and I. Irwin. 1983. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:979-980. http://dx.doi.org/10.1126/science.6823561
46. Lee, M.K., W. Stirling, Y. Xu, X. Xu, D. Qui, A.S. Mandir, T.M. Dawson, N.G. Copeland, N.A. Jenkins, and D.L. Price. 2002. Human alphasynuclein-harboring familial Parkinson's disease-linked Ala-53 -> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA. 99:8968-8973. http://dx.doi.org/10.1073/pnas.132197599
47. Lee, J., W.M. Zhu, D. Stanic, D.I. Finkelstein, M.H. Horne, J. Henderson, A.J. Lawrence, L. O'Connor, D. Tomas, J. Drago, and M.K. Horne. 2008. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain. 131:1574-1587. http://dx.doi .org/10.1093/brain/awn085
48. Lee, J.R., J.K. Kim, S.J. Lee, and K.P. Kim. 2009. Role of protein tyrosine nitration in neurodegenerative diseases and atherosclerosis. Arch. Pharm. Res. 32:1109-1118. http://dx.doi.org/10.1007/s12272-009-1802-0
49. Leong, S.L., C.L. Pham, D. Galatis, M.T. Fodero-Tavoletti, K. Perez, A.F. Hill, C.L. Masters, F.E. Ali, K.J. Barnham, and R. Cappai. 2009. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation. Free Radic. Biol. Med. 46:1328-1337. http://dx.doi.org/10.1016/j.freeradbiomed.2009.02.009
50. Lewis, J., R. Laforest, T. Buettner, S. Song, Y. Fujibayashi, J. Connett, and M. Welch. 2001. Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy. Proc. Natl. Acad. Sci. USA. 98:1206-1211. http://dx.doi.org/10.1073/pnas.98.3.1206
51. LeWitt, P.A. 2004. Clinical trials of neuroprotection for Parkinson's disease. Neurology. 63:S23-S31.
52. Lewy, F.H. 1912. Paralysis Agitans. I. Pathologische Antomie. In: Lewandowsky, M. (ed.) Handbuch der Neurologie. Berlin: Julius Springer.
53. Lim, Y., V.M. Kehm, E.B. Lee, J.H. Soper, C. Li, J.Q. Trojanowski, and V.M.Y. Lee. 2011. α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J. Neurosci. 31:10076-10087. http://dx.doi.org/10.1523/JNEUROSCI.0618-11.2011
54. Maries, E., B. Dass, T.J. Collier, J.H. Kordower, and K. Steece-Collier. 2003. The role of α-synuclein in Parkinson's disease: insights from animal models. Nat. Rev. Neurosci. 4:727-738. http://dx.doi.org/10.1038/nrn1199
55. Martin, L.J., Y. Pan, A.C. Price, W. Sterling, N.G. Copeland, N.A. Jenkins, D.L. Price, and M.K. Lee. 2006. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26:41-50. http://dx.doi.org/10.1523/JNEUROSCI.4308-05.2006
56. Matsuura, K., H. Kabuto, H. Makino, and N. Ogawa. 1997. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods. 73:45-48. http://dx.doi.org/10.1016/S0165-0270(96)02211-X
57. Meredith, G.E., and U.J. Kang. 2006. Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov. Disord. 21:1595-1606. http://dx.doi.org/10.1002/mds.21010
58. Meredith, G.E., S. Totterdell, E. Petroske, K. Santa Cruz, R.C. Callison Jr., and Y.S. Lau. 2002. Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res. 956:156-165. http://dx.doi.org/10.1016/S0006-8993(02)03514-X
59. Meredith, G.E., P.K. Sonsalla, and M.F. Chesselet. 2008. Animal models of Parkinson's disease progression. Acta Neuropathol. 115:385-398. http://dx.doi.org/10.1007/s00401-008-0350-x
60. Nebot, C., M. Moutet, P. Huet, J.Z. Xu, J.C. Yadan, and J. Chaudiere. 1993. Spectrophotometric assay of superoxide dismutase activity based on the activated autoxidation of a tetracyclic catechol. Anal. Biochem. 214:442-451. http://dx.doi.org/10.1006/abio.1993.1521
61. Neystat, M., T. Lynch, S. Przedborski, N. Kholodilov, M. Rzhetskaya, and R.E. Burke. 1999. Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease. Mov. Disord. 14:417-422.
62. Obeso, J.A., M.C. Rodriguez-Oroz, C.G. Goetz, C. Marin, J.H. Kordower, M. Rodriguez, E.C. Hirsch, M. Farrer, A.H. Schapira, and G. Halliday. 2010. Missing pieces in the Parkinson's disease puzzle. Nat. Med. 16:653-661. http://dx.doi.org/10.1038/nm.2165
63. Oehlberg, K., F.K. Barg, G.K. Brown, D. Taraborelli, M.B. Stern, and D. Weintraub. 2008. Attitudes regarding the etiology and treatment of depression in Parkinson's disease: a qualitative study. J. Geriatr. Psychiatry Neurol. 21:123-132. http://dx.doi.org/10.1177/0891988708316862
64. Ogawa, N., Y. Hirose, S. Ohara, T. Ono, and Y. Watanabe. 1985. A simple quantitative bradykinesia test in MPTP-treated mice. Res. Commun. Chem. Pathol. Pharmacol. 50:435-441.
65. Ogawa, N., K. Mizukawa, Y. Hirose, S. Kajita, S. Ohara, and Y. Watanabe. 1987. MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior. Eur. Neurol. 26:16-23. http://dx.doi.org/10.1159/000116351
66. Pakkenberg, B., A. Møller, H.J. Gundersen, A. Mouritzen Dam, and H. Pakkenberg. 1991. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J. Neurol. Neurosurg. Psychiatry. 54:30-33. http://dx.doi.org/10.1136/jnnp.54.1.30
67. Parish, C.L., D.I. Finkelstein, J. Drago, E. Borrelli, and M.K. Horne. 2001. The role of dopamine receptors in regulating the size of axonal arbors. J. Neurosci. 21:5147-5157.
68. Parkinson, J. 2002. An essay on the shaking palsy. 1817. J. Neuropsychiatry Clin. Neurosci. 14:223-236. http://dx.doi.org/10.1176/appi.neuropsych.14.2.223
69. Parkinson Study Group. 2004. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology. 62:330-332.
70. Parkinson Study Group PRECEPT Investigators. 2007. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology. 69:1480-1490. http://dx.doi.org/10.1212/01.wnl.0000277648.63931.c0
71. Paxinou, E., Q. Chen, M. Weisse, B.I. Giasson, E.H. Norris, S.M. Rueter, J.Q. Trojanowski, V.M. Lee, and H. Ischiropoulos. 2001. Induction of α-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21: 8053-8061.
72. Pham, C.L., S.L. Leong, F.E. Ali, V.B. Kenche, A.F. Hill, S.L. Gras, K.J. Barnham, and R. Cappai. 2009. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and offpathway aggregation of alpha-synuclein in a pH-dependent manner. J. Mol. Biol. 387:771-785. http://dx.doi.org/10.1016/j.jmb.2009.02.007
73. Pierucci, M., S. Galati, M. Valentino, V. Di Matteo, A. Benigno, R. Muscat, A. Pitruzzella, and G. Di Giovanni. 2011. Nitric Oxide Modulation Of The Basal Ganglia Circuitry: Therapeutic Implication For Parkinson's Disease And Other Motor Disorders. CNS Neurol. Disord. Drug Targets. (Epub ahead of print).
74. Presgraves, S.P., T. Ahmed, S. Borwege, and J.N. Joyce. 2004. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox. Res. 5:579-598. http://dx.doi.org/10.1007/BF03033178
75. Przedborski, S., V. Jackson-Lewis, R. Yokoyama, T. Shibata, V.L. Dawson, and T.M. Dawson. 1996. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. USA. 93:4565-4571. http://dx.doi .org/10.1073/pnas.93.10.4565
76. Przedborski, S., Q.P. Chen, M. Vila, B.I. Giasson, R. Djaldatti, S. Vukosavic, J.M. Souza, V. Jackson-Lewis, V.M.Y. Lee, and H. Ischiropoulos. 2001. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Neurochem. 76:637-640. http://dx.doi .org/10.1046/j.1471-4159.2001.00174.x
77. Przedborski, S., V. Jackson-Lewis, M. Vila, D.C. Wu, P. Teismann, K. Tieu, D.K. Choi, and O. Cohen. 2003. Free radical and nitric oxide toxicity in Parkinson's disease. Adv. Neurol. 91:83-94.
78. Reynolds, M.R., R.W. Berry, and L.I. Binder. 2007. Nitration in neurodegeneration: deciphering the "Hows" "nYs". Biochemistry. 46:7325-7336. http://dx.doi.org/10.1021/bi700430y
79. Saporito, M.S., E.M. Brown, M.S. Miller, and S. Carswell. 1999. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. J. Pharmacol. Exp. Ther. 288:421-427.
80. Schapira, A.H.V. 2008. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 7:97-109. http://dx.doi.org/10.1016/S1474-4422(07)70327-7
81. Schlüter, O.M., F. Fornai, M.G. Alessandrí, S. Takamori, M. Geppert, R. Jahn, and T.C. Südhof. 2003. Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience. 118:985-1002. http://dx.doi.org/10.1016/S0306-4522(03)00036-8
82. Schulz, J.B. 2008. Update on the pathogenesis of Parkinson's disease. J. Neurol. 255:3-7. http://dx.doi.org/10.1007/s00415-008-5011-4
83. Schulz, J.B., R.T. Matthews, M.M. Muqit, S.E. Browne, and M.F. Beal. 1995. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64:936-939. http://dx.doi.org/10.1046/j.1471-4159.1995.64020936.x
84. Sedelis, M., R.K. Schwarting, and J.P. Huston. 2001. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125:109-125. http://dx.doi.org/10.1016/S0166-4328(01)00309-6
85. Soon, C.P., P.S. Donnelly, B.J. Turner, L.W. Hung, P.J. Crouch, N.A. Sherratt, J.L. Tan, N.K. Lim, L. Lam, L. Bica, et al. 2011. Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J. Biol. Chem. 286:44035-44044. http://dx.doi.org/10.1074/jbc.M111.274407
86. Souza, J.M., B.I. Giasson, Q. Chen, V.M. Lee, and H. Ischiropoulos. 2000. Dityrosine cross-linking promotes formation of stable α -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275:18344-18349. http://dx.doi.org/10.1074/jbc.M000206200
87. Stanic, D., D.I. Finkelstein, D.W. Bourke, J. Drago, and M.K. Horne. 2003a. Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat. Eur. J. Neurosci. 18:1175-1188. http://dx.doi .org/10.1046/j.1460-9568.2003.02800.x
88. Stanic, D., C.L. Parish, W.M. Zhu, E.V. Krstew, A.J. Lawrence, J. Drago, D.I. Finkelstein, and M.K. Horne. 2003b. Changes in function and ultrastructure of striatal dopaminergic terminals that regenerate following partial lesions of the SNpc. J. Neurochem. 86:329-343. http://dx.doi .org/10.1046/j.1471-4159.2003.01843.x
89. Stowe, R.L., N.J. Ives, C. Clarke, J. van Hilten, J. Ferreira, R.J. Hawker, L. Shah, K. Wheatley, and R. Gray. 2008. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst. Rev. (2):CD006564.
90. Szabó, C., H. Ischiropoulos, and R. Radi. 2007. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat. Rev. Drug Discov. 6:662-680. http://dx.doi.org/10.1038/nrd2222
91. Terzioglu, M., and D. Galter. 2008. Parkinson's disease: genetic versus toxininduced rodent models. FEBS J. 275:1384-1391. http://dx.doi.org/10.1111/j.1742-4658.2008.06302.x
92. Thomas, B., and M.F. Beal. 2007. Parkinson's disease. Hum. Mol. Genet. 16:R183-R194. http://dx.doi.org/10.1093/hmg/ddm159
93. Trackey, J.L., T.F. Uliasz, and S.J. Hewett. 2001. SIN-1-induced cytotoxicity in mixed cortical cell culture: peroxynitrite-dependent and -independent induction of excitotoxic cell death. J. Neurochem. 79:445-455. http://dx.doi.org/10.1046/j.1471-4159.2001.00584.x
94. Trost, M., S. Su, P. Su, R.F. Yen, H.M. Tseng, A. Barnes, Y. Ma, and D. Eidelberg. 2006. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage. 31:301-307. http://dx.doi.org/10.1016/j.neuroimage.2005.12.024
95. Wang, J.L., S. Oya, A.K. Parhi, B.P. Lieberman, K. Ploessl, C. Hou, and H.F. Kung. 2010. In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease. Nucl. Med. Biol. 37:479-486. http://dx.doi.org/10.1016/j.nucmedbio.2010.01.006
96. Watabe, M., and T. Nakaki. 2008. Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells. Mol. Pharmacol. 74:933-940. http://dx.doi.org/10.1124/mol.108.048546
97. Weintraub, D., C.L. Comella, and S. Horn. 2008. Parkinson's disease-Part 3: Neuropsychiatric symptoms. Am. J. Manag. Care. 14:S59-S69.
98. West, M.J., and H.J. Gundersen. 1990. Unbiased stereological estimation of the number of neurons in the human hippocampus. J. Comp. Neurol. 296:1-22. http://dx.doi.org/10.1002/cne.902960102
99. Wills, J., J. Credle, T. Haggerty, J.-H. Lee, A.W. Oaks, and A. Sidhu. 2011. Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease. PLoS ONE. 6:e17953. http://dx.doi.org/10.1371/journal.pone.0017953
100. Yu, W.H., Y. Matsuoka, I. Sziráki, A. Hashim, J. Lafrancois, H. Sershen, and K.E. Duff. 2008. Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein. Neurochem. Res. 33:902-911. http://dx.doi.org/10.1007/s11064-007-9533-4
101. Yu, Z.W., X.H. Xu, Z.H. Xiang, J.F. Zhou, Z.H. Zhang, C. Hu, and C. He. 2010. Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS ONE. 5:e9956. http://dx.doi.org/10.1371/journal.pone.0009956
102. Zhang, M.Y., N. Kagan, M.L. Sung, M.M. Zaleska, and M. Monaghan. 2008. Sensitive and selective liquid chromatography/tandem mass spectrometry methods for quantitative analysis of 1-methyl-4-phenyl pyridinium (MPP+) in mouse striatal tissue. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 874:51-56. http://dx.doi.org/10.1016/j.jchromb.2008.08.030